MTX115325 (i.g.; 15 mg/kg and 50 mg/kg; twice daily for 10 weeks) reduces phosphorylated S129-αSyn levels and decreases the total area of GFAP staining in AAV-A53T-SNCA Mouse Model, indicating lower astrocyte activation[1].
MTX115325 (i.g.; 10 mg/kg; single dose) demonstrates excellent oral bioavailability (98%) and good CNS penetration with a brain partition coefficient (Kpu,u) of approximately 0.4[1].
MTX115325 (i.g.; single dose) has a Cmax of 7546.9 ng/mL at 15 mg/kg and a Cmax of 16374.3 ng/mL at 50 mg/kg. At a 50 mg/kg dosage, the drug concentration consistently remained above the EC50 for TOM20 ubiquitination[1].
| Animal Model: | AAV-A53T-SNCA Mouse Model [1] |
| Dosage: | 15 mg/kg and 50 mg/kg |
| Administration: | i.g.; twice daily for 10 weeks |
| Result: | Reduced the loss of dopaminergic neurons in the substantia nigra (SN) and preserved dopamine levels in the striatum.
Increased the percentage of tyrosine hydroxylase (TH)+ neurons. |
